FLT3 Inhibitor Covalent Binding Resolves Mutant Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for acute myeloid leukemia (AML) with FLT3 gene mutations, particularly TKD mutations, face challenges in effectively inhibiting mutant FLT3 activity, leading to drug resistance and relapse, with existing FLT3 inhibitors showing attenuated efficacy against certain mutant forms.
Innovation Solution
A pharmaceutical composition comprising a specific nitrogen-containing heterocyclic compound or its salt, represented by General Formula [1], which effectively inhibits mutant FLT3, particularly TKD mutations, by binding to FLT3 via a specific covalent bond, thereby blocking the activity of FLT3 and its mutant forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing FLT3 inhibitors are used to treat FLT3 mutation-positive cancer, then some therapeutic effect is achieved, but drug resistance and relapse occur due to attenuated efficacy against certain mutant forms
Solution Approach 1:
The patent modifies the chemical structure parameters of FLT3 inhibitors by introducing specific substituents at defined positions in the molecular framework. This structural parameter change enables the inhibitor to maintain binding affinity to wild-type FLT3 while gaining the ability to inhibit mutant forms such as D835Y and D835H, thereby resolving the contradiction between therapeutic efficacy and effectiveness against mutant forms
Solution Approach 2:
The patent introduces specific functional groups and substituents at localized positions (defined by variables in the general formula) of the inhibitor molecule. These local structural modifications create specific interactions with mutant FLT3 residues, allowing the inhibitor to selectively target mutant forms without sacrificing activity against wild-type FLT3, thus resolving the adaptability-efficacy contradiction
2Productivity
If conventional chemotherapies are used for AML with FLT3 mutations, then initial treatment response is achieved, but relapse and resistance develop leading to poor prognosis
Solution Approach 1:
The patent designs inhibitors with pre-optimized structural features that anticipate and prevent resistance development. The molecular structure includes specific substituents that are configured to maintain binding capability to both wild-type and mutant FLT3, creating a preliminary defensive mechanism against the development of resistance and relapse, thereby extending the duration of therapeutic effect
Solution Approach 2:
The patent creates a multi-functional inhibitor that can simultaneously target wild-type FLT3 and multiple mutant forms (including D835Y, D835H, and other TKD mutations). This universal inhibitor provides sustained therapeutic action by preventing both initial treatment failure and subsequent relapse, thus resolving the contradiction between initial response and duration of effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound demonstrates strong inhibitory effects on FLT3 and its mutant forms, including those resistant to other inhibitors, as evidenced by low IC50 values in enzyme inhibition assays and cell growth assays, indicating its potential as a potent anticancer agent for FLT3 mutation-positive cancers.
Implementation Method 1
which effectively inhibits mutant FLT3, particularly TKD mutations, by binding to FLT3 via a specific covalent bond
Data Source
Figure 1
AI summary
Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.